Quinolinic Acid

Quinolinic Acid

SCHEMBL1897909

O=C(O)c1cccnc1C(=O)O.[Mn]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.96
ALDH1A1 P00352 5/20 0.96
ALOX15 P16050 3/20 0.96
MAPT P10636 2/20 0.96
CYP3A4 P08684 1/20 0.96
TSHR P16473 1/20 0.96
BLM P54132 1/20 0.96
AGER Q15109 1/20 0.96
NPSR1 Q6W5P4 1/20 0.96
L3MBTL1 Q9Y468 1/20 0.96
TDP1 Q9NUW8 1/20 0.63
NAPRT Q6XQN6 2/20 0.59
LMNA P02545 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
CYP1A2 P05177 1/20 0.53
GAA P10253 2/20 0.53
ASPH Q12797 2/20 0.52
KDM8 Q8N371 2/20 0.52
DHODH Q02127 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quinolinic Acid SCHEMBL343618 0.98 KDM4E (1.00) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL69230 0.98 KDM4E (1.00) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL27676801 0.98 KDM4E (1.00) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL29356188 0.98 KDM4E (1.00) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL5361020 0.96 KDM4E (0.96) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL3744925 0.96 KDM4E (0.96) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL5674125 0.96 KDM4E (0.96) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL21326209 0.96 KDM4E (0.96) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL890367 0.96 KDM4E (0.96) KDM4EALDH1A1ALOX15MAPTCYP3A4
Quinolinic Acid SCHEMBL5381551 0.96 KDM4E (0.96) KDM4EALDH1A1ALOX15MAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117986601-A Vanadium 1, 4-naphthalene dicarboxylic acid coordination polymer and preparation method and application thereof 合肥通用机械研究院有限公司 2024-05-07 CN disclosed
EP-2496565-B1 Process for preparing divinylarene dioxides DOW GLOBAL TECHNOLOGIES LLC (US) 2014-08-13 EP disclosed
US-8716503-B2 Process for preparing divinylarene dioxides DOW GLOBAL TECHNOLOGIES LLC (US) 2014-05-06 US disclosed
EP-2496565-A1 PROCESS FOR PREPARING DIVINYLARENE DIOXIDES Dow Global Technologies LLC (US) 2012-09-12 EP disclosed
US-20120209015-A1 PROCESS FOR PREPARING DIVINYLARENE DIOXIDES BLUE CUBE IP LLC 2012-08-16 US disclosed
WO-2011056381-A1 PROCESS FOR PREPARING DIVINYLARENE DIOXIDES 1/6DOW GLOBAL TECHNOLOGIES LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120209015-A1 PROCESS FOR PREPARING DIVINYLARENE DIOXIDES SCO2, PPOX, SQLE KDM4E 1567/4885ALDH1A1 1769/4885ALOX15 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.